W
William G. Ondo
Researcher at Cornell University
Publications - 254
Citations - 22284
William G. Ondo is an academic researcher from Cornell University. The author has contributed to research in topics: Restless legs syndrome & Essential tremor. The author has an hindex of 74, co-authored 242 publications receiving 20124 citations. Previous affiliations of William G. Ondo include Baylor College of Medicine & Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.
Richard P. Allen,Daniel L. Picchietti,Michael Auerbach,Yong Won Cho,James R. Connor,Christopher J. Earley,Diego Garcia-Borreguero,Suresh Kotagal,Mauro Manconi,William G. Ondo,Jan Ulfberg,John W. Winkelman +11 more
TL;DR: Consensus recommendations based on clinical practice are presented, including when to use oral iron or IV iron, and recommendations on repeated iron treatments.
Journal ArticleDOI
Association of Single-Nucleotide Polymorphisms of the Tau Gene With Late-Onset Parkinson Disease
Eden R. Martin,William K. Scott,Martha Nance,Ray L. Watts,Jean P. Hubble,William C. Koller,Kelly E. Lyons,Rajesh Pahwa,Matthew B. Stern,Amy Colcher,Bradley C. Hiner,Joseph Jankovic,William G. Ondo,Fred H. Allen,Christopher G. Goetz,Gary W. Small,Donna Masterman,Frank L. Mastaglia,Nigel G. Laing,Jeffrey M. Stajich,Robert C. Ribble,Michael W. Booze,Allison R. Rogala,Michael A. Hauser,Fengyu Zhang,Rachel A. Gibson,Lefkos T. Middleton,Allen D. Roses,Jonathan L. Haines,Burton L. Scott,Margaret A. Pericak-Vance,Jeffery M. Vance +31 more
TL;DR: This integrated approach of genetic linkage and positional association analyses implicates tau as a susceptibility gene for idiopathic PD.
Journal ArticleDOI
Predictors of impulsivity and reward seeking behavior with dopamine agonists.
TL;DR: Three hundred consecutive patients taking DA either for Parkinson's disease, restless legs syndrome, or both were interviewed about changes in gambling, spending, sexual activity, or other impulsive activities subsequent to DA, and regression models identified risk factors for impulsivity.
Journal ArticleDOI
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1.
Juliane Winkelmann,Darina Czamara,Barbara Schormair,Franziska Knauf,Eva C. Schulte,Claudia Trenkwalder,Yves Dauvilliers,Olli Polo,Birgit Högl,Klaus Berger,Andrea Fuhs,Nadine Gross,Karin Stiasny-Kolster,Wolfgang H. Oertel,Cornelius G. Bachmann,Walter Paulus,Lan Xiong,Jacques Montplaisir,Guy A. Rouleau,Ingo Fietze,Jana Vavrova,David Kemlink,Karel Sonka,Sona Nevsimalova,Siong Chi Lin,Zbigniew K. Wszolek,Carles Vilariño-Güell,Matthew J. Farrer,Viola Gschliesser,Birgit Frauscher,Tina Falkenstetter,Werner Poewe,Richard P. Allen,Christopher J. Earley,William G. Ondo,Wei Dong Le,Derek Spieler,Maria Kaffe,Alexander Zimprich,Johannes Kettunen,Johannes Kettunen,Markus Perola,Markus Perola,Kaisa Silander,Kaisa Silander,Isabelle Cournu-Rebeix,Isabelle Cournu-Rebeix,Marcella Francavilla,Marcella Francavilla,Claire Fontenille,Claire Fontenille,Bertrand Fontaine,Bertrand Fontaine,Pavel Vodicka,Holger Prokisch,Peter Lichtner,Paul E. Peppard,Juliette Faraco,Emmanuel Mignot,Christian Gieger,Thomas Illig,H.-Erich Wichmann,Bertram Müller-Myhsok,Thomas Meitinger +63 more
TL;DR: Six RLS susceptibility loci of genome-wide significance are identified, two of them novel: an intergenic region on chromosome 2p14 (rs6747972), and a locus on 16q12.1 (rs3104767), a linkage disequilibrium block of 140 kb containing the 5′-end of TOX3 and the adjacent non-coding RNA BC034767.
Journal ArticleDOI
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
Robert A. Hauser,Ann Hsu,Sherron Kell,Alberto J. Espay,Kapil D. Sethi,Mark Stacy,William G. Ondo,Martin O'Connell,Suneel K. Gupta +8 more
TL;DR: Extended-release carbidopa-levodopa might be a useful treatment for patients with Parkinson's disease who have motor fluctuations, with potential benefits including decreased off-time and reduced levodopa dosing frequency.